ChemoCentryx, Inc.

ChemoCentryx, Inc.

ChemoCentryx, Inc.

Overview
Date Founded

1996

Headquarters

850 Maude Avenue, Mountain View, CA, 94043, USA

Type of Company

Public

Employees (Worldwide)

76

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Contact Data
Trying to get in touch with decision makers at ChemoCentryx, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Senior Vice President, Drug Discovery & Chief Scientific Officer

Senior Vice President, Head of Pharmaceutics

Senior Vice President, Head of Commercial

Chief Business Officer & Treasurer

Chief Financial & Administrative Officer, Senior Vice President

Senior Vice President, Clinical Development

Executive Director Pharmaceutical Development

Controller

Director

Board of Directors

Founder at ChemoCentryx, Inc.

Chairman Emeritus at Business Roundtable

Former Chief Medical Officer at Pfizer, Inc.

Former Vice President-Pharmaceutical Development at Abbott Laboratories

Paths to ChemoCentryx, Inc.
Potential Connections via
Relationship Science
You
ChemoCentryx, Inc.
Owners & Shareholders
Details Hidden

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

Details Hidden

Cormorant Asset Management manages a hedge fund and a private equity fund that focus on investments in the healthcare sector. The firm employs a fundamental, research intensive approach that focuses on primary research to identify investment opportunities.The objective of the hedge fund is to generate superior risk-adjusted returns with low market correlation. Cormorant seeks to accomplish this objective primarily through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. The firm invests substantially, but not solely, in publicly traded equity securities in the healthcare and life science industries.The private equity fund's investment objective is to generate significant long-term capital appreciation by creating or investing in market innovative companies in the biotechnology and life sciences marketplace. Cormorant expects to achieve this objective by primarily investing in \"crossover\" (or mezzanine) round or pre-IPO portfolio companies in the biotech, medical device, diagnostics, generics, pharmaceutical, specialty pharmaceutical and life science research tool sectors. Cormorant, may also invest in portfolio companies through PIPEs and in start-up portfolio companies, including start-ups organized, managed and funded with Cormorant's or their affiliates' proprietary capital.

Details Hidden

Consonance Capital Management's (CCM) funds seek to deliver exceptional, uncorrelated risk adjusted returns. CCM seeks to meet this objective by focusing on investment opportunities in the publicly traded stocks of healthcare companies. The firm invests in all sub-sectors of the healthcare sector including healthcare information technology, managed care, pharmaceuticals, specialty pharmaceuticals, commercial stage biotechnology, healthcare facilities and services, medical devices and supplies, diagnostics and consumer-based healthcare companies.CCM believes the public healthcare market lends itself to an active long/short strategy. The firm focuses on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The funds also invest in other types of securities and may use a variety of investment techniques to generate profit and/or control risk. These may include participating in swaps, buying or selling futures contracts, purchasing and writing options and other derivative contracts, purchasing or selling debt instruments, and trading on margin by borrowing funds and pledging securities as collateral. CCM invests primarily in healthcare companies in the US, and on an opportunistic basis in the rest of the world.^

Recent Transactions
Details Hidden

Vifor Pharma AG, Vifor (International) AG purchase ChemoCentryx, Inc. from GlaxoSmithKline Plc

Details Hidden

ChemoCentryx, Inc. issued USD Common Stock

Details Hidden

ChemoCentryx, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onChemoCentryx, Inc. issued USD Common Stock

Underwriter

Advised onChemoCentryx, Inc. issued USD Common Stock

Escrow Agent

Advised onChemoCentryx, Inc. issued USD Common Stock

Managing Director

Advised onChemoCentryx, Inc. issued USD Common Stock

Underwriter

Advised onChemoCentryx, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Consultant

Former Chief Medical Officer at ChemoCentryx, Inc.

Publicist

Senior Account Executive, Investor Relations-Client Services Team at Burns McClellan, Inc.

Clients

Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It offers products for iron deficiency, nephrology, and cardio-renal therapies. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland.

Key Stats and Financials As of 2018
Market Capitalization
$2.85B
Total Enterprise Value
$386M
Earnings Per Share
$-0.76
Revenue
$42.9M
Net Profit
$-38M
EBITDA
$-39.8M
EBITDAMargin
-92.73%
Total Debt
$19.7M
Total Equity
$14.8M
Enterprise Value Sales
9.01x
TEVNet Income
-10.17x
Debt TEV
0.05x
Five Year Compounded Annual Growth Rate Of Revenue
47.89%
Non-Profit Donations & Grants
Investors
Details Hidden

PGIM provides mezzanine financing for middle-market companies in located in North America. The firm focuses on companies that are pursuing a targeted market with a value-added product, process or service. They provides financing in the form of mezzanine and private debt.

Details Hidden

HBM Healthcare Investments AG is an investment company, which invests in the healthcare sector. Its primary business activity is the acquisition, holding and sale of equity interests in companies in the human medicine sector. The firm's focus of investment is on follow-on financing for existing portfolio companies. The company was founded on July 12, 2001 and is headquartered in Zug, Switzerland.

Details Hidden

Alta Partners Management Corp. specializes in investments in healthcare venture capital companies. The firm looks for Technology enabled solutions and services that improve delivery and quality of care with Strong entrepreneurs

Suppliers
Bio-Techne Corp. Industrial Machinery & Manufacturing | Minneapolis, MN

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Vivendi SA Media Conglomerates | Paris, France

Vivendi is one of the few multimedia groups in the world to operate across the entire digital value chain. It creates and publishes content for which it develops broadcast networks and distribution platforms. In a context of digital revolution and telecommunications industry change, the group capitalizes on both its employees’ expertise and its strong brands to continue to create value. Vivendi currently operates a number of companies that are leaders in content, media and telecommunications.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by ChemoCentryx, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of ChemoCentryx, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and ChemoCentryx, Inc..